Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients

References

• MackmanNTriggers, targets and treatments for thrombosisNature200845191491818288180
   PubMed Web of Science ®Google Scholar
• NiederlaenderECauses of death in the EU. Statistics in focus. Population and social conditionsEurostat200610112
   Google Scholar
• BouillaudJBDe [’Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general (Obliteration of the veins and its influence on the formation of partial dropsies: consideration of the general and passive dropsies)Arch Gen Med18231188204 French
   Google Scholar
• TrousseauAPhlegmasia alba dolensBaillièreJBClinique Medicale de VHotel-Dieu de Paris Volume 32nd edParis, FranceJB Bailliere and Sons1865
   Google Scholar
• HeitJASilversteinMDMohrDNPettersonTMO’FallonWMMeltonLJIIIRisk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control studyArch Intern Med200016080981510737280
   PubMed Web of Science ®Google Scholar
• ChewHKWunTHarveyDZhouHWhiteRHIncidence of venous thromboembolism and its effect on survival among patients with common cancersArch Intern Med200616645846416505267
   PubMed Web of Science ®Google Scholar
• SørensenHTSværkeCFarkasDKSuperficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancerEur J Cancer20124858659322129887
   PubMed Web of Science ®Google Scholar
• PrandoniPFalangaAPiccioliACancer and venous thromboembolismLancet Oncol2005640141015925818
   PubMed Web of Science ®Google Scholar
• FalangaADonatiMBPathogenesis of thrombosis in patients with malignancyInt JHematol20017313714411372723
   PubMed Web of Science ®Google Scholar
• FalangaARicklesFRManagement of thrombohemorrhagic syndromes (THS) in hematologic malignanciesHematology Am Soc Hematol Educ Program200716517118024625
   PubMedGoogle Scholar
• NalluriSRChuDKeresztesRZhuXWuSRisk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysisJAMA20083002277228519017914
   PubMed Web of Science ®Google Scholar
• PrandoniPLensingAWPiccioliARecurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood20021003484348812393647
   PubMed Web of Science ®Google Scholar
• GouldMKGarciaDAWrenSMPrevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e227Se277S22315263
   PubMedGoogle Scholar
• KahnSRLimWDunnASPrevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e195Se226S22315261
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAntithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e419Se494S22315268
   PubMed Web of Science ®Google Scholar
• FargeDDebourdeauPBeckersMInternational clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancerJ Thromb Haemost201311567023217107
   PubMed Web of Science ®Google Scholar
• MandalaMFalangaARoilaFManagement of venous thromboembolism [VTE] in cancer patients: ESMO Clinical Practice GuidelinesAnn Oncol201122Suppl 6vi85vi9221908511
   PubMed Web of Science ®Google Scholar
• LymanGHKhoranaAAFalangaAAmerican Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancerJ Clin Oncol2007255490550517968019
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Venous Thromboembolic Disease version 22011 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportiveAccessed October 23, 2012
   Google Scholar
• MannKGBrummelKButenasSWhat is all that thrombin for?J Thromb Haemost200311504151412871286
   PubMed Web of Science ®Google Scholar
• DavieEWKulmanJDAn overview of the structure and function of thrombinSemin Thromb Hemost200632 Suppl 131516673262
   PubMed Web of Science ®Google Scholar
• Siller-MatulaJMSchwameisMBlannAMannhalterCJilmaBThrombin as a multi-functional enzyme. Focus on in vitro and in vivo effectsThromb Haemost20111061020103321979864
   PubMed Web of Science ®Google Scholar
• HuLLeeMCampbellWPerez-SolerRKarpatkinSRole of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasisBlood20041042746275115265791
   PubMed Web of Science ®Google Scholar
• DeFeoKHayesCChernickMRynJVGilmourSKUse of dabigatran etexilate to reduce breast cancer progressionCancer Biol Ther2010101001100820798593
   PubMed Web of Science ®Google Scholar
• Gómez-OutesASuárez-GeaMLCalvo-RojasGDiscovery of anticoagulant drugs: a historical perspectiveCurr Drug Discov Technol201298310421838662
   PubMedGoogle Scholar
• ApostolakisSLipGYNovel oral anticoagulants: focus on the direct factor Xa inhibitor darexabanExpert Opin Investig Drugs20122110571064
   PubMed Web of Science ®Google Scholar
• AhrensIPeterKLipGYBodeCDevelopment and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigationDiscov Med20121344545022742650
   PubMed Web of Science ®Google Scholar
• ViskovCJustMLauxVMourierPLorenzMDescription of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026J Thromb Haemost200971143115119422447
   PubMed Web of Science ®Google Scholar
• DubrucCKarimi-AnderesiNLunvenCZhangMGrossmannMPotgieterHPharmacokinetics of a new, ultra-low molecular weight heparin, semuloparin (AVE5026), in healthy subjects. Results from the first phase I studiesBlood2009114 Abstract 1073
   Google Scholar
• Gómez-OutesASuárez-GeaMLLecumberriRRochaEPozo-HernándezCVargas-CastrillónENew parenteral anticoagulants in developmentTher Adv Cardiovasc Dis20115335921045018
   PubMedGoogle Scholar
• EikelboomJWWeitzJINew anticoagulantsCirculation20101211523153220368532
   PubMed Web of Science ®Google Scholar
• LassenMRFisherWMouretPAgnelliGSAVE InvestigatorsSemuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEEJ Thromb Haemost20121082283222429800
   PubMedGoogle Scholar
• FisherWAgnelliGGeorgeDExtended venous thromboembolism (VTE) prophylaxis after hip fracture surgery with the ultra-low-molecular-weight heparin (ULMWH) semuloparinPathophysiol Haemos Thromb2009/201037Suppl 1OC681
   Google Scholar
• TurpieAGGAgnelliGFisherWBenefit to-risk profile of the ultra-low-molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE): a meta-analysis of 3 major orthopaedic surgery studiesPathophysiol Haemos Thromb2009/201037Suppl 1OC332
   Google Scholar
• AgnelliGGeorgeDJKakkarAKSAVE-ONCO InvestigatorsSemuloparin for thromboprophylaxis in patients receiving chemotherapy for cancerN Engl J Med201236660160922335737
   PubMed Web of Science ®Google Scholar
• Sanof Research and DevelopmentNDA 203213. Semuloparin SodiumOncologic Drugs Advisory Committee Meeting, June 20, 2012 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM308562.pdfAccessed December 29, 2012
   Google Scholar
• Food and Drug Administration Briefing Document. NDA 203213. Semuloparin sodiumOncologic Drugs Advisory Committee Meeting June 20, 2012 Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm308561.pdfAccessed December 29, 2012
   Google Scholar
• KakkarAAgnelliGFisherWThe ultra-low-molecular-weight heparin semuloparin for prevention of venous thromboembolism in patients undergoing major abdominal surgeryAbstract 188 presented at the 52nd ASH Annual Meeting and ExpositionOrlando, FLDecember 4–7, 2010 Available from: https://ash.confex.com/ash/2010/webprogram/Paper31003.htmlAccessed December 29, 2012
   Google Scholar
• HerbertJMHéraultJPBernatABiochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharideBlood199891419742059596667
   PubMed Web of Science ®Google Scholar
• SaviPHeraultJPDuchaussoyPReversible biotinylated oligosaccharides. A new approach for a better management of anticoagulant therapyJ Thromb Haemost200861697170618647228
   PubMed Web of Science ®Google Scholar
• MaQFareedJIdraparinux sodium. Sanof-AventisI Drugs200471028103415551178
   PubMed Web of Science ®Google Scholar
• Veyrat-FolletCVivierNTrelluMDubrucCSanderinkGJThe pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from phase III clinical trialsJ Thromb Haemost2009755956519187079
   PubMed Web of Science ®Google Scholar
• HarenbergJJörgIVukojevicYMikusGWeissCAnticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trialsEur J Clin Pharmacol20086455556318283446
   PubMed Web of Science ®Google Scholar
• BullerHRCohenATDavidsonBvan Gogh InvestigatorsIdraparinux versus standard therapy for venous thromboembolic diseaseN Engl J Med20073571094110417855670
   PubMed Web of Science ®Google Scholar
• van DoormaalFFCohenATDavidsonBLIdraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trialThromb Haemost2010104869120508907
   PubMed Web of Science ®Google Scholar
• BullerHRCohenATDavidsonBvan Gogh InvestigatorsExtended prophylaxis of venous thromboembolism with idraparinuxN Engl J Med20073571105111217855671
   PubMed Web of Science ®Google Scholar
• HarenbergJVukojevicYMikusGJoergIWeissCLong elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trialsJ Thromb Haemost2008689089218315557
   PubMed Web of Science ®Google Scholar
• PatyITrelluMDestorsJMCortezPBoëlleESanderinkGReversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusionJ Thromb Haemost2010872272920088937
   PubMed Web of Science ®Google Scholar
• Equinox InvestigatorsEfficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosisJ Thromb Haemost201199299
   Web of Science ®Google Scholar
• BüllerHRGallusASPillionGPrinsMHRaskobGECassiopea InvestigatorsEnoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trialLancet201237912312922130488
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMVoithBZuehlsdorfMWensingGSafety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClin Pharmacol Ther20057841242116198660
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjectsEur J Clin Pharmacol20056187388016328318
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMRothAMueckWDose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurr Med Res Opin2008242757276518715524
   PubMed Web of Science ®Google Scholar
• LangDFreudenbergerCWeinzCIn vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humansDrug Metab Dispos2009371046105519196846
   PubMed Web of Science ®Google Scholar
• Xarelto®(rivaroxaban)Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfAccessed January 4, 2013
   Google Scholar
• ErikssonBIBorrisLCFriedmanRJRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplastyN Engl J Med20083582765277518579811
   PubMed Web of Science ®Google Scholar
• KakkarAKBrennerBDahlOEExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialLancet2008372313918582928
   PubMed Web of Science ®Google Scholar
• LassenMRAgenoWBorrisLCRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyN Engl J Med20083582776278618579812
   PubMed Web of Science ®Google Scholar
• TurpieAGLassenMRDavidsonBLRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialLancet20093731673168019411100
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med201136588389121830957
   PubMed Web of Science ®Google Scholar
• BauersachsRBerkowitzSDBrennerBEINSTEIN InvestigatorsOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med20103632499251021128814
   PubMed Web of Science ®Google Scholar
• BüllerHRPrinsMHLensinAWEINSTEIN-PE InvestigatorsOral rivaroxaban for the treatment of symptomatic pulmonary embolismN Engl J Med20123661287129722449293
   PubMed Web of Science ®Google Scholar
• CohenATSpiroTEBüllerHRExtended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolJ Thromb Thrombolysis20113140741621359646
   PubMed Web of Science ®Google Scholar
• CohenATSpiroTEBüllerHRRivaroxaban for thromboprophylaxis in acutely ill medical patientsN Engl J Med201336851352323388003
   PubMed Web of Science ®Google Scholar
• CohenATSpiroTEBullerHRRivaroxaban versus enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: Magellan subgroup analysesJ Thromb Hemost20119Suppl 2 Abstract O-MO-034
   Google Scholar
• WongPCCrainEJXinBApixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJ Thromb Haemost2008682082918315548
   PubMed Web of Science ®Google Scholar
• Eliquis®(apixaban)Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed January 8, 2013
   Google Scholar
• WangLZhangDRaghavanNIn vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studiesDrug Metab Dispos20103844845819940026
   PubMed Web of Science ®Google Scholar
• RaghavanNFrostCEYuZApixaban metabolism and pharmacokinetics after oral administration to humansDrug Metab Dispos200937748118832478
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDPortmanRJApixaban or enoxaparin for thromboprophylaxis after knee replacementN Engl J Med200936159460419657123
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAApixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialLancet201037580781520206776
   PubMed Web of Science ®Google Scholar
• LassenMRGallusARaskobGEApixaban versus enoxaparin for thromboprophylaxis after hip replacementN Engl J Med20103632487249821175312
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med201136598199221870978
   PubMed Web of Science ®Google Scholar
• LevineMNGuCLiebmanHAA randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancerJ Thromb Haemost20121080781422409262
   PubMed Web of Science ®Google Scholar
• GoldhaberSZLeizoroviczAKakkarAKApixaban versus enoxaparin for thromboprophylaxis in medically ill patientsN Engl J Med20113652167217722077144
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAApixaban for extended treatment of venous thromboembolismN Engl J Med201336869970823216615
   PubMed Web of Science ®Google Scholar
• FurugohriTIsobeKHondaYDU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJ Thromb Haemost200861542154918624979
   PubMed Web of Science ®Google Scholar
• MorishimaYHondaYKamisatoCComparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in ratsThromb Res201213051451922647432
   PubMed Web of Science ®Google Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol20105074375320081065
   PubMed Web of Science ®Google Scholar
• KawajiHIshiiMTamakiYSasakiKTakagiMEdoxaban for prevention of venous thromboembolism after major orthopedic surgeryOrthop Res Rev201245364
   Google Scholar
• BathalaMSMasumotoHOgumaTHeLLowrieCMendellJPharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humansDrug Metab Dispos2012402250225522936313
   PubMed Web of Science ®Google Scholar
• FujiTFujitaSTachibanaSEfficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trialBlood2010116 Abstract 3320
   Google Scholar
• FujiTWangCJFujitaSEdoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 TrialPathophysiol Haemost Thromb201037Suppl 1 Abstract A20
   Google Scholar
• FujitaSFujiTTachibanaSNakamuraKawaiYSafety and efficacy of edoxaban in patients undergoing hip fracture surgeryPathophysiol Haemost Thromb201037Suppl 1 Abstract A95
   Google Scholar
• FujiTFujitaSTachibanaSKawaiYEdoxaban versus enoxaparin for the prevention of venous thromboembolism: pooled analysis of venous thromboembolism and bleeding from STARS E-III and STARS J-VBlood2011118 Abstract 208
   Google Scholar
• WeitzJIConnollySJPatelIRandomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThromb Haemost201010463364120694273
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPAntmanEMEvaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Am Heart J201016063564120934556
   PubMed Web of Science ®Google Scholar
• ZhangPHuangWWangLDiscovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitorBioorg Med Chem Lett2009192179218519297154
   PubMed Web of Science ®Google Scholar
• AbeKSiuGEdwardsSAnimal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral factor Xa inhibitorBlood2006108 Abstract 901
   Web of Science ®Google Scholar
• HutchaleelahaAYeCSongYLorenzTGretlerDLambingJLMetabolism and disposition of betrixaban and its lack of interaction with major CYP enzymesBlood2012120 Abstract 2266
   Web of Science ®Google Scholar
• TurpieAGBauerKADavidsonBLA randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)Thromb Haemost2009101687619132191
   PubMed Web of Science ®Google Scholar
• EzekowitzMDA phase 2, randomized, parallel group, dose-finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open-label dose-adjusted warfarin in patients with non-valvular atrial fibrillation (EXPLORE-Xa)Presented at the American College of Cardiology 59th Annual Scientific SessionsAtlanta, GAMarch 14–16, 2010 Available from: http://assets.cardiosource.com/ezekowitz_explore1.ppt#636,1,EXPLORE-XaAccessed January 7, 2013
   Google Scholar
• MungallDBIBR-1048 Boehringer IngelheimCurr Opin Investig Drugs20023905907
   PubMedGoogle Scholar
• StangierJClinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilateClin Pharmacokinet20084728529518399711
   PubMed Web of Science ®Google Scholar
• TrocónizIFTillmannCLiesenfeldKHSchäferHGStangierJPopulation pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgeryJ Clin Pharmacol20074737138217322149
   PubMed Web of Science ®Google Scholar
• BlechSEbnerTLudwig-SchwellingerEStangierJRothWThe metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humansDrug Metab Dispos20083638639918006647
   PubMed Web of Science ®Google Scholar
• Pradaxa®(dabigatran)Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdfAccessed January 8, 2013
   Google Scholar
• ErikssonBIDahlOERosencherNDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialLancet200737094995617869635
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOEHuoMHKurthAAHantelSHermanssonKOral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trialThromb Haemost201110572172921225098
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNOral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trialJ Thromb Haemost200752178218517764540
   PubMed Web of Science ®Google Scholar
• GinsbergJSDavidsonBLCompPCRE-MOBILIZE Writing CommitteeOral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgeryJ Arthroplasty2009241918534438
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med20093611139115119717844
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med20093612342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKSchellongSMA randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II)Blood2011118 Abstract 205
   Google Scholar
• SchulmanSKearonCKakkarAKExtended use of dabigatran, warfarin, or placebo in venous thromboembolismN Engl J Med201336870971823425163
   PubMed Web of Science ®Google Scholar
• SchulmanSBaanstraDErikssonHBenefit of extended maintenance therapy for venous thromboembolism with dabigatran etexilate is maintained over 1 year of post-treatment follow-upBlood2012120 Abstract 21
   Web of Science ®Google Scholar
• AklEASchünemannHJRoutine heparin for patients with cancer? One answer, more questionsN Engl J Med201236666166222335745
   PubMed Web of Science ®Google Scholar
• PrinsMHLeguetPGiletHRoborel de ClimensAConvenience of the new long-acting anticoagulant idraparinux (IDRA) versus vitamin K antagonist (vitamin K antagonist) in patients with deep venous thrombosis (DVT)J Thromb Haemost20075Suppl 2 Abstract P-T-552
   Google Scholar
• BorsigLHeparin as an inhibitor of cancer progressionProg Mol Biol Transl Sci20109333534920807651
   PubMed Web of Science ®Google Scholar
• StevensonJLChoiSHVarkiADifferential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activityClin Cancer Res20051119 Pt 17003701116203794
   PubMedGoogle Scholar
• KhoranaAASahniAAltlandODFrancisCWHeparin inhibition of endothelial cell proliferation and organization is dependent on molecular weightArterioscler Thromb Vasc Biol2003232110211512920044
   PubMed Web of Science ®Google Scholar
• LinkinsLADansALMooresLKTreatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e495Se530S22315270
   PubMed Web of Science ®Google Scholar
• KrauelKHackbarthCFürllBGreinacherAHeparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodiesBlood20121191248125522049520
   PubMed Web of Science ®Google Scholar
• WalengaJMPrechelMJeskeWPRivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopeniaBr J Haematol2008143929918671707
   PubMed Web of Science ®Google Scholar